Published in Cancer Res on April 10, 2013
Targeting bromodomains: epigenetic readers of lysine acetylation. Nat Rev Drug Discov (2014) 3.54
Chromatin proteins and modifications as drug targets. Nature (2013) 2.60
Dual kinase-bromodomain inhibitors for rationally designed polypharmacology. Nat Chem Biol (2014) 2.28
Functions of BET proteins in erythroid gene expression. Blood (2015) 1.50
A chemical probe toolbox for dissecting the cancer epigenome. Nat Rev Cancer (2017) 1.40
Epigenetic stress responses induce muscle stem-cell ageing by Hoxa9 developmental signals. Nature (2016) 1.38
RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain. Proc Natl Acad Sci U S A (2013) 1.35
Acetyl-lysine binding site of bromodomain-containing protein 4 (BRD4) interacts with diverse kinase inhibitors. ACS Chem Biol (2014) 1.29
Discovery and development of the Polo-like kinase inhibitor volasertib in cancer therapy. Leukemia (2014) 1.28
Cancer epigenetics drug discovery and development: the challenge of hitting the mark. J Clin Invest (2014) 1.20
Bromodomain protein BRD4 is required for estrogen receptor-dependent enhancer activation and gene transcription. Cell Rep (2014) 1.19
Assessing cellular efficacy of bromodomain inhibitors using fluorescence recovery after photobleaching. Epigenetics Chromatin (2014) 1.14
Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery. Oncotarget (2015) 1.06
BET and HDAC inhibitors induce similar genes and biological effects and synergize to kill in Myc-induced murine lymphoma. Proc Natl Acad Sci U S A (2014) 1.05
Protein lysine acetylation by p300/CBP. Chem Rev (2015) 1.02
The bromodomain: from epigenome reader to druggable target. Biochim Biophys Acta (2014) 1.02
Affinity map of bromodomain protein 4 (BRD4) interactions with the histone H4 tail and the small molecule inhibitor JQ1. J Biol Chem (2014) 1.01
Brd4 is essential for IL-1β-induced inflammation in human airway epithelial cells. PLoS One (2014) 1.01
[1,2,4]triazolo[4,3-a]phthalazines: inhibitors of diverse bromodomains. J Med Chem (2013) 1.01
Discovery of a Chemical Tool Inhibitor Targeting the Bromodomains of TRIM24 and BRPF. J Med Chem (2015) 0.99
Discovery of novel small-molecule inhibitors of BRD4 using structure-based virtual screening. J Med Chem (2013) 0.99
BET protein inhibitor JQ1 attenuates Myc-amplified MCC tumor growth in vivo. Cancer Res (2014) 0.98
Nanog requires BRD4 to maintain murine embryonic stem cell pluripotency and is suppressed by bromodomain inhibitor JQ1 together with Lefty1. Stem Cells Dev (2014) 0.97
Generation of a Selective Small Molecule Inhibitor of the CBP/p300 Bromodomain for Leukemia Therapy. Cancer Res (2015) 0.97
Structure-Guided Design of IACS-9571, a Selective High-Affinity Dual TRIM24-BRPF1 Bromodomain Inhibitor. J Med Chem (2015) 0.96
CBP30, a selective CBP/p300 bromodomain inhibitor, suppresses human Th17 responses. Proc Natl Acad Sci U S A (2015) 0.95
Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review. Mol Cancer (2015) 0.94
S6K2: The Neglected S6 Kinase Family Member. Front Oncol (2013) 0.92
Open access target validation is a more efficient way to accelerate drug discovery. PLoS Biol (2015) 0.90
CXCL8 histone H3 acetylation is dysfunctional in airway smooth muscle in asthma: regulation by BET. Am J Physiol Lung Cell Mol Physiol (2015) 0.87
Biased multicomponent reactions to develop novel bromodomain inhibitors. J Med Chem (2014) 0.87
The BET bromodomain inhibitor, JQ1, facilitates c-FLIP degradation and enhances TRAIL-induced apoptosis independent of BRD4 and c-Myc inhibition. Oncotarget (2015) 0.87
Privileged diazepine compounds and their emergence as bromodomain inhibitors. Chem Biol (2014) 0.86
Selective targeting of the BRG/PB1 bromodomains impairs embryonic and trophoblast stem cell maintenance. Sci Adv (2015) 0.86
ROR nuclear receptors: structures, related diseases, and drug discovery. Acta Pharmacol Sin (2014) 0.86
Bromodomain Inhibitor Review: Bromodomain and Extra-terminal Family Protein Inhibitors as a Potential New Therapy in Central Nervous System Tumors. Cureus (2016) 0.85
The bromodomain and extra-terminal inhibitor CPI203 enhances the antiproliferative effects of rapamycin on human neuroendocrine tumors. Cell Death Dis (2014) 0.84
9H-purine scaffold reveals induced-fit pocket plasticity of the BRD9 bromodomain. J Med Chem (2015) 0.84
Discovery and Characterization of GSK2801, a Selective Chemical Probe for the Bromodomains BAZ2A and BAZ2B. J Med Chem (2015) 0.83
BET inhibition as a new strategy for the treatment of gastric cancer. Oncotarget (2016) 0.81
Immunomodulatory drugs target IKZF1-IRF4-MYC axis in primary effusion lymphoma in a cereblon-dependent manner and display synergistic cytotoxicity with BRD4 inhibitors. Oncogene (2015) 0.80
Effect of BET Missense Mutations on Bromodomain Function, Inhibitor Binding and Stability. PLoS One (2016) 0.78
Preclinical activity of CPI-0610, a novel small molecule bromodomain and extra-terminal protein inhibitor in the therapy of multiple myeloma. Leukemia (2016) 0.78
Epigenetic blockade of neoplastic transformation by bromodomain and extra-terminal (BET) domain protein inhibitor JQ-1. Biochem Pharmacol (2016) 0.78
BRD4-targeted therapy induces Myc-independent cytotoxicity in Gnaq/11-mutatant uveal melanoma cells. Oncotarget (2015) 0.77
Promiscuous targeting of bromodomains by bromosporine identifies BET proteins as master regulators of primary transcription response in leukemia. Sci Adv (2016) 0.76
BET inhibitors in the treatment of hematologic malignancies: current insights and future prospects. Onco Targets Ther (2016) 0.76
Erythropoiesis provides a BRD's eye view of BET protein function. Drug Discov Today Technol (2016) 0.76
A Novel Phenanthridionone Based Scaffold As a Potential Inhibitor of the BRD2 Bromodomain: Crystal Structure of the Complex. PLoS One (2016) 0.75
Identification of novel potent human testis-specific and bromodomain-containing protein (BRDT) inhibitors using crystal structure-based virtual screening. Int J Mol Med (2016) 0.75
Bromodomains in Protozoan Parasites: Evolution, Function, and Opportunities for Drug Development. Microbiol Mol Biol Rev (2017) 0.75
Frapid: achieving full automation of FRAP for chemical probe validation. Biomed Opt Express (2016) 0.75
Applying (89)Zr-Transferrin To Study the Pharmacology of Inhibitors to BET Bromodomain Containing Proteins. Mol Pharm (2016) 0.75
Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science (1999) 83.27
c-Myc-regulated microRNAs modulate E2F1 expression. Nature (2005) 31.81
Selective inhibition of BET bromodomains. Nature (2010) 18.79
BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell (2011) 14.34
c-Myc regulates transcriptional pause release. Cell (2010) 11.64
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature (2011) 11.44
Structure and ligand of a histone acetyltransferase bromodomain. Nature (1999) 10.08
Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature (2011) 8.29
VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat Med (2004) 6.40
Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proc Natl Acad Sci U S A (2011) 6.30
The double bromodomain protein Brd4 binds to acetylated chromatin during interphase and mitosis. Proc Natl Acad Sci U S A (2003) 5.59
Hoxa9 transforms primary bone marrow cells through specific collaboration with Meis1a but not Pbx1b. EMBO J (1998) 5.21
Histone recognition and large-scale structural analysis of the human bromodomain family. Cell (2012) 5.15
The structural basis for the recognition of acetylated histone H4 by the bromodomain of histone acetyltransferase gcn5p. EMBO J (2000) 4.82
A bromodomain protein, MCAP, associates with mitotic chromosomes and affects G(2)-to-M transition. Mol Cell Biol (2000) 4.27
Cdc25 cell-cycle phosphatase as a target of c-myc. Nature (1996) 4.23
The Hox genes and their roles in oncogenesis. Nat Rev Cancer (2010) 3.97
Stabilization of N-Myc is a critical function of Aurora A in human neuroblastoma. Cancer Cell (2009) 3.92
Shared and separate functions of polo-like kinases and aurora kinases in cancer. Nat Rev Cancer (2010) 3.74
Identification of CDK4 as a target of c-MYC. Proc Natl Acad Sci U S A (2000) 3.38
Brd4 marks select genes on mitotic chromatin and directs postmitotic transcription. Mol Biol Cell (2009) 3.29
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A (2007) 3.21
Differential expression of homeobox genes in functionally distinct CD34+ subpopulations of human bone marrow cells. Proc Natl Acad Sci U S A (1994) 3.08
Sensing centromere tension: Aurora B and the regulation of kinetochore function. Trends Cell Biol (2010) 2.88
Cooperative binding of two acetylation marks on a histone tail by a single bromodomain. Nature (2009) 2.83
Pathogenesis of NUT midline carcinoma. Annu Rev Pathol (2011) 2.55
Bromodomains as therapeutic targets. Expert Rev Mol Med (2011) 2.52
c-Myc regulates cyclin D-Cdk4 and -Cdk6 activity but affects cell cycle progression at multiple independent points. Mol Cell Biol (1999) 2.50
Mitotic mechanics: the auroras come into view. Curr Opin Cell Biol (2003) 2.31
Structural basis of lysine-acetylated HIV-1 Tat recognition by PCAF bromodomain. Mol Cell (2002) 2.20
Aurora kinase inhibitors--rising stars in cancer therapeutics? Mol Cancer Ther (2010) 1.91
Sister chromatid tension and the spindle assembly checkpoint. Curr Opin Cell Biol (2009) 1.80
Array CGH identifies distinct DNA copy number profiles of oncogenes and tumor suppressor genes in chromosomal- and microsatellite-unstable sporadic colorectal carcinomas. J Mol Med (Berl) (2006) 1.69
Therapeutic potential of a synthetic lethal interaction between the MYC proto-oncogene and inhibition of aurora-B kinase. Proc Natl Acad Sci U S A (2010) 1.65
Regulation of aurora B expression by the bromodomain protein Brd4. Mol Cell Biol (2009) 1.60
Identification of a chemical probe for bromo and extra C-terminal bromodomain inhibition through optimization of a fragment-derived hit. J Med Chem (2012) 1.55
Aurora kinase A-specific T-cell receptor gene transfer redirects T lymphocytes to display effective antileukemia reactivity. Blood (2011) 1.54
Higher-throughput, label-free, real-time molecular interaction analysis. Anal Biochem (2006) 1.47
Microarray-based screening for molecular markers in medulloblastoma revealed STK15 as independent predictor for survival. Cancer Res (2004) 1.45
Aurora kinase inhibitors. Crit Rev Oncol Hematol (2009) 1.08
Malignant hematopoietic cell lines: in vitro models for the study of MLL gene alterations. Leukemia (2004) 1.05
The discovery of the potent aurora inhibitor MK-0457 (VX-680). Bioorg Med Chem Lett (2009) 1.04
Crystal structure of human aurora B in complex with INCENP and VX-680. J Med Chem (2012) 0.87
The Aurora A and B kinases are up-regulated in bone marrow-derived chronic lymphocytic leukemia cells and represent potential therapeutic targets. Haematologica (2012) 0.82
Genome-wide association study identifies novel breast cancer susceptibility loci. Nature (2007) 29.23
International network of cancer genome projects. Nature (2010) 20.35
Selective inhibition of BET bromodomains. Nature (2010) 18.79
A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature (2008) 16.10
BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell (2011) 14.34
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature (2011) 11.44
Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science (2007) 10.60
Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell (2013) 8.37
Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet (2013) 8.24
Transcriptional amplification in tumor cells with elevated c-Myc. Cell (2012) 8.24
A common coding variant in CASP8 is associated with breast cancer risk. Nat Genet (2007) 7.35
HDAC2 negatively regulates memory formation and synaptic plasticity. Nature (2009) 6.96
Epigenetic protein families: a new frontier for drug discovery. Nat Rev Drug Discov (2012) 6.70
Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics. PLoS Genet (2008) 6.22
Lung cancer susceptibility locus at 5p15.33. Nat Genet (2008) 5.99
The RIDDLE syndrome protein mediates a ubiquitin-dependent signaling cascade at sites of DNA damage. Cell (2009) 5.96
Tea drinking habits and oesophageal cancer in a high risk area in northern Iran: population based case-control study. BMJ (2009) 5.79
A genome-wide association study of lung cancer identifies a region of chromosome 5p15 associated with risk for adenocarcinoma. Am J Hum Genet (2009) 5.62
PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res (2007) 5.45
Histone recognition and large-scale structural analysis of the human bromodomain family. Cell (2012) 5.15
Direct inhibition of the NOTCH transcription factor complex. Nature (2009) 4.82
Alcohol drinking in never users of tobacco, cigarette smoking in never drinkers, and the risk of head and neck cancer: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. J Natl Cancer Inst (2007) 4.55
Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. J Natl Cancer Inst (2010) 4.54
Exposure to diesel motor exhaust and lung cancer risk in a pooled analysis from case-control studies in Europe and Canada. Am J Respir Crit Care Med (2010) 4.35
The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. Science (2013) 4.20
Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: a report from the InterLymph Consortium. Lancet Oncol (2006) 4.13
Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors. Clin Cancer Res (2008) 4.02
Alcohol and cause-specific mortality in Russia: a retrospective case-control study of 48,557 adult deaths. Lancet (2009) 4.01
Protein production and purification. Nat Methods (2008) 3.97
A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci. Nat Genet (2010) 3.93
Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc Natl Acad Sci U S A (2005) 3.86
Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium. Blood (2008) 3.81
Linear motif atlas for phosphorylation-dependent signaling. Sci Signal (2008) 3.77
Investigation of the fine structure of European populations with applications to disease association studies. Eur J Hum Genet (2008) 3.65
Large-scale structural analysis of the classical human protein tyrosine phosphatome. Cell (2009) 3.51
Small-molecule inhibition of BRDT for male contraception. Cell (2012) 3.50
Crystal structure of the tetrameric Mad1-Mad2 core complex: implications of a 'safety belt' binding mechanism for the spindle checkpoint. EMBO J (2002) 3.42
Interaction between tobacco and alcohol use and the risk of head and neck cancer: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. Cancer Epidemiol Biomarkers Prev (2009) 3.33
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A (2007) 3.21
Replication of lung cancer susceptibility loci at chromosomes 15q25, 5p15, and 6p21: a pooled analysis from the International Lung Cancer Consortium. J Natl Cancer Inst (2010) 3.18
Targeting MYCN in neuroblastoma by BET bromodomain inhibition. Cancer Discov (2013) 3.11
HMGB1 is an endogenous immune adjuvant released by necrotic cells. EMBO Rep (2004) 3.00
Genome-wide association study of renal cell carcinoma identifies two susceptibility loci on 2p21 and 11q13.3. Nat Genet (2010) 2.96
Critical residues for structure and catalysis in short-chain dehydrogenases/reductases. J Biol Chem (2002) 2.95
BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia. Blood (2012) 2.91
Mcl-1 expression has in vitro and in vivo significance in chronic lymphocytic leukemia and is associated with other poor prognostic markers. Blood (2008) 2.88
Evaluation of human papillomavirus antibodies and risk of subsequent head and neck cancer. J Clin Oncol (2013) 2.87
Tumor necrosis factor (TNF) and lymphotoxin-alpha (LTA) polymorphisms and risk of non-Hodgkin lymphoma in the InterLymph Consortium. Am J Epidemiol (2010) 2.86
Renal cell carcinoma in relation to cigarette smoking: meta-analysis of 24 studies. Int J Cancer (2005) 2.73
The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs. Proc Natl Acad Sci U S A (2006) 2.73
Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium. Hum Mol Genet (2011) 2.72
Oral health and risk of squamous cell carcinoma of the head and neck and esophagus: results of two multicentric case-control studies. Am J Epidemiol (2007) 2.64
FGFR2 variants and breast cancer risk: fine-scale mapping using African American studies and analysis of chromatin conformation. Hum Mol Genet (2009) 2.62
Occupational exposure to crystalline silica and risk of lung cancer: a multicenter case-control study in Europe. Epidemiology (2007) 2.60
Genetic polymorphisms in the base excision repair pathway and cancer risk: a HuGE review. Am J Epidemiol (2005) 2.54
Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia. Proc Natl Acad Sci U S A (2009) 2.54
Multiple ADH genes are associated with upper aerodigestive cancers. Nat Genet (2008) 2.53
Bromodomains as therapeutic targets. Expert Rev Mol Med (2011) 2.52
Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins. Proc Natl Acad Sci U S A (2012) 2.52
Distinct effects of STAT5 activation on CD4+ and CD8+ T cell homeostasis: development of CD4+CD25+ regulatory T cells versus CD8+ memory T cells. J Immunol (2003) 2.47
Structural coupling of SH2-kinase domains links Fes and Abl substrate recognition and kinase activation. Cell (2008) 2.46
The bromodomain protein Brd4 insulates chromatin from DNA damage signalling. Nature (2013) 2.46
Genome-wide association study of follicular lymphoma identifies a risk locus at 6p21.32. Nat Genet (2010) 2.37
The structure of P-TEFb (CDK9/cyclin T1), its complex with flavopiridol and regulation by phosphorylation. EMBO J (2008) 2.36
Structural basis of inhibitor specificity of the human protooncogene proviral insertion site in moloney murine leukemia virus (PIM-1) kinase. J Med Chem (2005) 2.34
Structure of the pseudokinase VRK3 reveals a degraded catalytic site, a highly conserved kinase fold, and a putative regulatory binding site. Structure (2009) 2.33
The (un)targeted cancer kinome. Nat Chem Biol (2010) 2.33
Exogenous high-mobility group box 1 protein induces myocardial regeneration after infarction via enhanced cardiac C-kit+ cell proliferation and differentiation. Circ Res (2005) 2.32
Small-molecule kinase inhibitors provide insight into Mps1 cell cycle function. Nat Chem Biol (2010) 2.26
TP53 and KRAS mutation load and types in lung cancers in relation to tobacco smoke: distinct patterns in never, former, and current smokers. Cancer Res (2005) 2.24
Structure of the CaMKIIdelta/calmodulin complex reveals the molecular mechanism of CaMKII kinase activation. PLoS Biol (2010) 2.22
Programmed death 1 signaling on chronic myeloid leukemia-specific T cells results in T-cell exhaustion and disease progression. Blood (2009) 2.20
BET bromodomains mediate transcriptional pause release in heart failure. Cell (2013) 2.17
Genetic variants on 15q25.1, smoking, and lung cancer: an assessment of mediation and interaction. Am J Epidemiol (2012) 2.16
The incidence and pathophysiology of hyponatraemia after subarachnoid haemorrhage. Clin Endocrinol (Oxf) (2006) 2.16
Cancer-associated IDH2 mutants drive an acute myeloid leukemia that is susceptible to Brd4 inhibition. Genes Dev (2013) 2.12
Activation segment dimerization: a mechanism for kinase autophosphorylation of non-consensus sites. EMBO J (2008) 2.12
Fluorous-based small-molecule microarrays for the discovery of histone deacetylase inhibitors. Angew Chem Int Ed Engl (2007) 2.11
The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo. Blood (2010) 2.09
Opium use and risk of mortality from digestive diseases: a prospective cohort study. Am J Gastroenterol (2013) 2.07
Opium use and mortality in Golestan Cohort Study: prospective cohort study of 50,000 adults in Iran. BMJ (2012) 2.07
Specific CLK inhibitors from a novel chemotype for regulation of alternative splicing. Chem Biol (2011) 2.06
Clinicopathologic features and long-term outcomes of NUT midline carcinoma. Clin Cancer Res (2012) 2.06